[1] World Health Organization. Golobal tuberculosis report 2019[R]. Geneva: WHO, 2019:27-70. [2] Maningi NE, Malinga LA, Antiabong JF, et al. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa[J]. BMC Infect Dis, 2017, 17(1):795-802. [3] Siddiqui S, Brooks MB, Malik AA, et al. Evaluation of GenoType MTBDRplus for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Karachi, Pakistan[J]. PLoS One, 2019,14(8):e0221485. [4] Pitso L, Potgieter S, Van der Spoel van Dijk A, Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa[J]. S Afr Med J, 2019, 109(9):659-664. [5] 国家卫生和计划生育委员会.肺结核诊断: WS 288-2017[S]. 北京:人民卫生出版社,2017:1-22. [6] 赵雁林, 逄宇. 结核病实验室检验规程[M]. 北京: 人民卫生出版社, 2015:39-138. [7] 汪敏, 李静, 张阳奕, 等. 2013—2017年上海市结核病耐药状况及影响因素分析[J]. 中国防痨杂志, 2019, 41(12):1269-1276. [8] Song WM, Li YF, Ma XB et al. Primary drug resistance of Mycobacterium tuberculosis in Shandong, China, 2004-2018[J]. Respir Res, 2019, 20(1):223-235. [9] Lin HC,Perng CL,Lai YW,et al. Molecular screening of multidrug-resistance tuberculosis by a designated public health laboratory in Taiwan[J]. Eur J Clin Microbiol Infect Dis, 2017, 36(12):2431-2439. [10] Folkvardsen DB,Svensson E,Thomsen,et al. Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis[J]. J Clin Microbiol, 2013, 51(5):1596-1599. [11] Zheng C, Li S, Luo Z, et al. Mixed infections and rifampin heteroresistance among Mycobacterium tuberculosis clinical isolates[J]. J Clin Microbiol, 2015, 53(7):2138-2147. [12] 刘元, 周俊, 崔晓利, 等. 基因芯片与线性探针技术检测涂阳肺结核患者痰标本MTB耐药性的价值[J]. 中国防痨杂志, 2019, 41(7):738-742. [13] 中华医学会结核病学分会临床检验专业委员会. 结核病病原学分子诊断专家共识[J]. 中华结核与呼吸杂志, 2018, 41(9):688-693. [14] 李敏, 李大兴, 杨奇, 等. 结核分枝杆菌利福平分子药敏结果与其表型药敏差异的研究[J]. 实用预防医学, 2019, 26(1):46-50. [15] 吴雪琼. 加强结核病耐药性检测研究提高正确解读检测结果水平[J]. 中国防痨杂志, 2019, 41(2):124-128.
2021, Vol. 28 
